New and incremental FDA black box warnings from 2008 to 2015

Michael T. Solotke, Sanket S. Dhruva, Nicholas S. Downing, Nilay D Shah, Joseph S. Ross

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The boxed warning (also known as ‘black box warning [BBW]’) is one of the strongest drug safety actions that the U.S. Food & Drug Administration (FDA) can implement, and often warns of serious risks. The objective of this study was to comprehensively characterize BBWs issued for drugs after FDA approval. Methods: We identified all post-marketing BBWs from January 2008 through June 2015 listed on FDA’s MedWatch and Drug Safety Communications websites. We used each drug’s prescribing information to classify its BBW as new, major update to a preexisting BBW, or minor update. We then characterized these BBWs with respect to pre-specified BBW-specific and drug-specific features. Results: There were 111 BBWs issued to drugs on the US market, of which 29% (n = 32) were new BBWs, 32% (n = 35) were major updates, and 40% (n = 44) were minor updates. New BBWs and major updates were most commonly issued for death (51%) and cardiovascular risk (27%). The new BBWs and major updates impacted 200 drug formulations over the study period, of which 64% were expected to be used chronically and 58% had available alternatives without a BBW. Conclusions: New BBWs and incremental updates to existing BBWs are frequently added to drug labels after regulatory approval.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalExpert Opinion on Drug Safety
DOIs
StateAccepted/In press - Dec 17 2017

Fingerprint

Drug Labeling
Pharmaceutical Preparations
Safety
Drug Prescriptions
Drug Compounding
Marketing
Food

Keywords

  • Black box warning
  • boxed warning
  • drug labeling
  • drug safety
  • food and drug administration

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

New and incremental FDA black box warnings from 2008 to 2015. / Solotke, Michael T.; Dhruva, Sanket S.; Downing, Nicholas S.; Shah, Nilay D; Ross, Joseph S.

In: Expert Opinion on Drug Safety, 17.12.2017, p. 1-7.

Research output: Contribution to journalArticle

Solotke, Michael T. ; Dhruva, Sanket S. ; Downing, Nicholas S. ; Shah, Nilay D ; Ross, Joseph S. / New and incremental FDA black box warnings from 2008 to 2015. In: Expert Opinion on Drug Safety. 2017 ; pp. 1-7.
@article{f3715b4c72a94be6836edf1795aaa40a,
title = "New and incremental FDA black box warnings from 2008 to 2015",
abstract = "Background: The boxed warning (also known as ‘black box warning [BBW]’) is one of the strongest drug safety actions that the U.S. Food & Drug Administration (FDA) can implement, and often warns of serious risks. The objective of this study was to comprehensively characterize BBWs issued for drugs after FDA approval. Methods: We identified all post-marketing BBWs from January 2008 through June 2015 listed on FDA’s MedWatch and Drug Safety Communications websites. We used each drug’s prescribing information to classify its BBW as new, major update to a preexisting BBW, or minor update. We then characterized these BBWs with respect to pre-specified BBW-specific and drug-specific features. Results: There were 111 BBWs issued to drugs on the US market, of which 29{\%} (n = 32) were new BBWs, 32{\%} (n = 35) were major updates, and 40{\%} (n = 44) were minor updates. New BBWs and major updates were most commonly issued for death (51{\%}) and cardiovascular risk (27{\%}). The new BBWs and major updates impacted 200 drug formulations over the study period, of which 64{\%} were expected to be used chronically and 58{\%} had available alternatives without a BBW. Conclusions: New BBWs and incremental updates to existing BBWs are frequently added to drug labels after regulatory approval.",
keywords = "Black box warning, boxed warning, drug labeling, drug safety, food and drug administration",
author = "Solotke, {Michael T.} and Dhruva, {Sanket S.} and Downing, {Nicholas S.} and Shah, {Nilay D} and Ross, {Joseph S.}",
year = "2017",
month = "12",
day = "17",
doi = "10.1080/14740338.2018.1415323",
language = "English (US)",
pages = "1--7",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - New and incremental FDA black box warnings from 2008 to 2015

AU - Solotke, Michael T.

AU - Dhruva, Sanket S.

AU - Downing, Nicholas S.

AU - Shah, Nilay D

AU - Ross, Joseph S.

PY - 2017/12/17

Y1 - 2017/12/17

N2 - Background: The boxed warning (also known as ‘black box warning [BBW]’) is one of the strongest drug safety actions that the U.S. Food & Drug Administration (FDA) can implement, and often warns of serious risks. The objective of this study was to comprehensively characterize BBWs issued for drugs after FDA approval. Methods: We identified all post-marketing BBWs from January 2008 through June 2015 listed on FDA’s MedWatch and Drug Safety Communications websites. We used each drug’s prescribing information to classify its BBW as new, major update to a preexisting BBW, or minor update. We then characterized these BBWs with respect to pre-specified BBW-specific and drug-specific features. Results: There were 111 BBWs issued to drugs on the US market, of which 29% (n = 32) were new BBWs, 32% (n = 35) were major updates, and 40% (n = 44) were minor updates. New BBWs and major updates were most commonly issued for death (51%) and cardiovascular risk (27%). The new BBWs and major updates impacted 200 drug formulations over the study period, of which 64% were expected to be used chronically and 58% had available alternatives without a BBW. Conclusions: New BBWs and incremental updates to existing BBWs are frequently added to drug labels after regulatory approval.

AB - Background: The boxed warning (also known as ‘black box warning [BBW]’) is one of the strongest drug safety actions that the U.S. Food & Drug Administration (FDA) can implement, and often warns of serious risks. The objective of this study was to comprehensively characterize BBWs issued for drugs after FDA approval. Methods: We identified all post-marketing BBWs from January 2008 through June 2015 listed on FDA’s MedWatch and Drug Safety Communications websites. We used each drug’s prescribing information to classify its BBW as new, major update to a preexisting BBW, or minor update. We then characterized these BBWs with respect to pre-specified BBW-specific and drug-specific features. Results: There were 111 BBWs issued to drugs on the US market, of which 29% (n = 32) were new BBWs, 32% (n = 35) were major updates, and 40% (n = 44) were minor updates. New BBWs and major updates were most commonly issued for death (51%) and cardiovascular risk (27%). The new BBWs and major updates impacted 200 drug formulations over the study period, of which 64% were expected to be used chronically and 58% had available alternatives without a BBW. Conclusions: New BBWs and incremental updates to existing BBWs are frequently added to drug labels after regulatory approval.

KW - Black box warning

KW - boxed warning

KW - drug labeling

KW - drug safety

KW - food and drug administration

UR - http://www.scopus.com/inward/record.url?scp=85038375330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038375330&partnerID=8YFLogxK

U2 - 10.1080/14740338.2018.1415323

DO - 10.1080/14740338.2018.1415323

M3 - Article

C2 - 29215916

AN - SCOPUS:85038375330

SP - 1

EP - 7

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

ER -